Trial · NCT07886788
Study of Grape Consumption in Adaptation to Seasonal Photoperiod
NCT07886788, Not applicable, Active not recruiting, University Rovira i Virgili
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Grape Consumption in Adaptation to Seasonal Photoperiod. Trials, record NCT07886788. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886788
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Grape Consumption in Adaptation to Seasonal Photoperiod
- NCT number
- NCT07886788
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 46 participants, actual
- Lead sponsor
- University Rovira i Virgili
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Overweight, Obesity & Overweight
- Interventions
- Freeze-Dried Grape Powder, Plain Low-Fat Yogurt, Mediterranean-Style Dietary Guidance
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes38
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in circulating plasma microRNA expression | Baseline (week 0), end of intervention (week 3), and end of follow-up (week 5). | Differential expression of circulating microRNAs in plasma, comparing changes from baseline between the grape supplementation and control arms at the end of the intervention and after follow-up. |
| Secondary | Change in DNA methylation in promoter regions of selected genes | Baseline (week 0), end of intervention (week 3), and end of follow-up (week 5). | Changes in DNA methylation in the promoter regions of selected genes, measured by pyrosequencing after bisulfite treatment of DNA isolated from peripheral blood mononuclear cells (PBMCs). Changes from baseline will be compared between the grape supplementation and control arms at the end of the intervention and after follow-up. |
| Secondary | Change in serum metabolomic profile | Baseline (week 0), end of intervention (week 3), and end of follow-up (week 5). | Changes in the serum metabolomic profile assessed by proton nuclear magnetic resonance (1H-NMR). Changes from baseline will be compared between the grape supplementation and control arms at the end of the intervention and after follow-up. |
| Secondary | Change in gut microbiota diversity and composition | Baseline (week 0), end of intervention (week 3), and end of follow-up (week 5). | Changes in bacterial diversity and composition assessed by 16S ribosomal RNA gene sequencing of stool samples. Changes from baseline will be compared between the grape supplementation and control arms at the end of the intervention and after follow-up. |
| Secondary | Change in body weight | Baseline (week 0), end of intervention (week 3), and end of follow-up (week 5). | Change in body weight, measured in kilograms, from baseline to the end of the intervention and follow-up, comparing the grape supplementation and control arms. |
| Secondary | Change in body mass index | Baseline (week 0), end of intervention (week 3), and end of follow-up (week 5). | Change in body mass index (BMI), calculated as body weight in kilograms divided by height in meters squared (kg/m²), from baseline to the end of the intervention and follow-up, comparing the grape supplementation and control arms. |
| Secondary | Change in waist circumference | Baseline (week 0), end of intervention (week 3), and end of follow-up (week 5). | Change in waist circumference, measured in centimeters, from baseline to the end of the intervention and follow-up, comparing the grape supplementation and control arms. |
| Secondary | Change in body composition assessed by bioelectrical impedance | Baseline (week 0), end of intervention (week 3), and end of follow-up (week 5). | Changes in body composition assessed using a TANITA bioelectrical impedance device, comparing changes from baseline between the grape supplementation and control arms at the end of the intervention and follow-up. |
| Secondary | Change in systolic and diastolic blood pressure | Baseline (week 0), end of intervention (week 3), and end of follow-up (week 5). | Changes in resting systolic and diastolic blood pressure, measured in mmHg using two readings taken one minute apart. Changes from baseline will be compared between the grape supplementation and control arms at the end of the intervention and follow-up. |
| Secondary | Change in resting heart rate | Baseline (week 0), end of intervention (week 3), and end of follow-up (week 5). | Change in resting heart rate, measured in beats per minute, from baseline to the end of the intervention and follow-up, comparing the grape supplementation and control arms. |
1 to 10 of 38Source ClinicalTrials.gov
See all 38 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers13
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07886788
GET https://conductscience.org/api/trials/v1/NCT07886788/registered?page=2